Table 4.
Absolute annual cost of control outcomes with once-weekly semaglutide 0.5 and 1.0 mg, and dulaglutide 0.75 and 1.5 mg in 2018 US dollars
| Endpoint | Once-weekly semaglutide 0.5 mg (USD) | Once-weekly semaglutide 1.0 mg (USD) | Dulaglutide 0.75 mg (USD) | Dulaglutide 1.5 mg (USD) |
|---|---|---|---|---|
| HbA1c < 7.0% without hypoglycemia, and no weight gain | 13,778 | 11,916 | 20,041 | 15,204 |
| HbA1c < 6.5% | 17,996 | 13,161 | 25,936 | 18,762 |
| HbA1c < 7.0% | 12,968 | 11,162 | 16,958 | 13,161 |
| Weight loss ≥ 5% | 20,041 | 13,997 | 38,340 | 29,394 |
| Weight loss ≥ 10% | 62,987 | 32,660 | 293,939 | 110,227 |
| ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss | 16,638 | 12,968 | 35,273 | 25,195 |
HbA1c glycated hemoglobin